Optimizing assessments of rate of progression in Parkinson disease (PD) is important in designing clinical trials, especially of potential disease-modifying agents.
To examine the value of measures of impairment, disability, and quality of life in assessing progression in early PD.
Design, Setting, and Participants...
JAMA Neurol. Published online April 07, 2014. doi:10.1001/jamaneurol.2014.391